Home

Moltiplicazione attuale sconnessione 17 aag clinical trials opzione ricordi ufficio postale

The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and  inhibits graft versus host disease development | Oncogene
The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development | Oncogene

Structural development of HSP90 inhibitors. Geldanamycin (I) and... |  Download Scientific Diagram
Structural development of HSP90 inhibitors. Geldanamycin (I) and... | Download Scientific Diagram

The germline component of 17-AAG drug susceptibility. a... | Download  Scientific Diagram
The germline component of 17-AAG drug susceptibility. a... | Download Scientific Diagram

Targeting Heat Shock Protein 90 for the Treatment of Malignant  Pheochromocytoma | PLOS ONE
Targeting Heat Shock Protein 90 for the Treatment of Malignant Pheochromocytoma | PLOS ONE

The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated  up-regulation of HSP70 in brain cancer cells | PLOS ONE
The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells | PLOS ONE

Tanespimycin - an overview | ScienceDirect Topics
Tanespimycin - an overview | ScienceDirect Topics

APExBIO - 17-AAG (KOS953)|Hsp90 inhibitor|CAS# 75747-14-7
APExBIO - 17-AAG (KOS953)|Hsp90 inhibitor|CAS# 75747-14-7

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone  hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 | PNAS
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 | PNAS

Frontiers | Inhibition of Heat Shock Protein 90 by 17-AAG Reduces  Inflammation via P2X7 Receptor/NLRP3 Inflammasome Pathway and Increases  Neurogenesis After Subarachnoid Hemorrhage in Mice | Molecular Neuroscience
Frontiers | Inhibition of Heat Shock Protein 90 by 17-AAG Reduces Inflammation via P2X7 Receptor/NLRP3 Inflammasome Pathway and Increases Neurogenesis After Subarachnoid Hemorrhage in Mice | Molecular Neuroscience

Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a  Liposarcoma Mouse Model | Anticancer Research
Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model | Anticancer Research

Altered states: selectively drugging the Hsp90 cancer chaperone: Trends in  Molecular Medicine
Altered states: selectively drugging the Hsp90 cancer chaperone: Trends in Molecular Medicine

New agents in cancer clinical trials | Oncogene
New agents in cancer clinical trials | Oncogene

Nanomedicines Targeting Heat Shock Protein 90 Gene Expression in the  Therapy of Breast Cancer - Zaib - 2022 - ChemistrySelect - Wiley Online  Library
Nanomedicines Targeting Heat Shock Protein 90 Gene Expression in the Therapy of Breast Cancer - Zaib - 2022 - ChemistrySelect - Wiley Online Library

Tanespimycin (17-AAG) | ≥99%(HPLC) | Selleck | HSP (HSP90) inhibitor
Tanespimycin (17-AAG) | ≥99%(HPLC) | Selleck | HSP (HSP90) inhibitor

Effect of 17-AAG on cell proliferation and Hsp90 client protein levels....  | Download Scientific Diagram
Effect of 17-AAG on cell proliferation and Hsp90 client protein levels.... | Download Scientific Diagram

Tanespimycin (17-AAG) | HSP90 Inhibitor | MedChemExpress
Tanespimycin (17-AAG) | HSP90 Inhibitor | MedChemExpress

Frontiers | Inhibition of Heat Shock Protein 90 by 17-AAG Reduces  Inflammation via P2X7 Receptor/NLRP3 Inflammasome Pathway and Increases  Neurogenesis After Subarachnoid Hemorrhage in Mice | Molecular Neuroscience
Frontiers | Inhibition of Heat Shock Protein 90 by 17-AAG Reduces Inflammation via P2X7 Receptor/NLRP3 Inflammasome Pathway and Increases Neurogenesis After Subarachnoid Hemorrhage in Mice | Molecular Neuroscience

In vitro study comparing the efficacy of the water-soluble HSP90  inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90  inhibitor, 17-AAG, in breast cancer cell lines
In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines

Frontiers | A Novel Mechanism of 17-AAG Therapeutic Efficacy on HSP90  Inhibition in MYCN-Amplified Neuroblastoma Cells | Oncology
Frontiers | A Novel Mechanism of 17-AAG Therapeutic Efficacy on HSP90 Inhibition in MYCN-Amplified Neuroblastoma Cells | Oncology

In vitro study comparing the efficacy of the water-soluble HSP90  inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90  inhibitor, 17-AAG, in breast cancer cell lines
In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines

17-AAG - ABILITY, TOXICITY, SOLUBILITY
17-AAG - ABILITY, TOXICITY, SOLUBILITY

Hsp90 Chaperone Inhibitor 17-AAG Attenuates Aβ-Induced Synaptic Toxicity  and Memory Impairment | Journal of Neuroscience
Hsp90 Chaperone Inhibitor 17-AAG Attenuates Aβ-Induced Synaptic Toxicity and Memory Impairment | Journal of Neuroscience

17-AAG
17-AAG

Spotlight on 17‐AAG as an Hsp90 inhibitor for molecular targeted cancer  treatment - Talaei - 2019 - Chemical Biology & Drug Design - Wiley  Online Library
Spotlight on 17‐AAG as an Hsp90 inhibitor for molecular targeted cancer treatment - Talaei - 2019 - Chemical Biology & Drug Design - Wiley Online Library

Ganetespib: research and clinical development | OTT
Ganetespib: research and clinical development | OTT